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Abstract
Background: TCF7L2 is a transcription factor involved in Wnt/β-catenin signaling which has a
variant known to be associated with risk of Type 2 diabetes and, in some studies, with risk of
certain cancers, including familial breast cancer. No studies of ovarian cancer have been reported
to date.
Methods: Two clinic-based case-control studies at the Mayo Clinic were assessed including 798
breast cancer cases, 843 breast cancer controls, 391 ovarian cancer cases, and 458 ovarian cancer
controls. Genotyping at TCF7L2 rs12255372 used a 5' endonuclease assay, and statistical analysis
used logistic regression among participants as a whole and among a priori-defined subsets.
Results: No associations with risk of breast or ovarian cancer were observed (ordinal model, p =
0.62 and p = 0.75, respectively). In addition, no associations were observed among sub-groups
defined by age, BMI, family history, stage, grade, histology, or tumor behavior.
Conclusion: Although the biology of the Wnt/β-catenin signaling pathway and prior association
between rs12255372 and numerous phenotypes warranted examination of this TCF7L2 SNP, no
compelling evidence for association with breast or ovarian cancer was observed.
Background
Transcription factor 7-like 2 (TCF7L2) encodes a tran-
scription factor involved in Wnt/β-catenin signaling path-
way which encompasses an intronic single-nucleotide
polymorphism (SNP, rs12255372) that has been associ-
ated with risk of Type 2 diabetes in linkage studies and
genome-wide association studies [1-4] with potential
modification by obesity [5]. TCF7L2 forms an active
nuclear complex with β-catenin that binds and induces
the expression of target genes involved in cellular prolifer-
ation, evasion of apoptosis, and tissue invasion and
metastasis. Because of the protein's relevance in this
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canonical cancer pathway, several cancer association stud-
ies have been conducted. Studies report associations with
increased risk of familial breast cancer [6] and aggressive-
ness of prostate cancer [7]; there are conflicting reports in
colon cancer showing decreased risk [8], increased risk
[9], or differential risk by NSAIDs use [10]. We sought to
assess the role of this polymorphism in risk of breast and
ovarian cancer and, based on other reports, in subsets
defined by body mass index (BMI), family history, and
measures of disease aggressiveness (e.g., stage, histologi-
cal subtypes).
Methods
Female participants were recruited at Mayo Clinic in
Rochester, MN. Invasive breast cancer cases (N = 798)
were over 18 years of age and enrolled within six months
of diagnosis. Invasive or borderline epithelial ovarian can-
cer cases (N = 391) were over 20 years of age and living in
the Upper Midwest enrolled within one year of diagnosis.
Controls (breast cancer N = 843; ovarian cancer N = 458)
were frequency-matched on age and region of residence
and seen for general medical examinations. Risk factor
information was collected through interviews, clinical
data was abstracted from medical records, and DNA was
extracted from peripheral blood (Gentra). All breast can-
cer participants and 98% of ovarian cancer participants
were white non-Hispanic. Details are provided elsewhere
[11,12].
Genotyping at TCF7L2  rs12255372 was performed on
384-well plates using TaqMan™ (Applied Biosystems). For
breast and ovarian cancer, respectively, call rates were
high (98.1%, 95.9%), genotypes were in Hardy-Weinberg
equilibrium (p = 0.23, p = 0.96), white non-Hispanic con-
trol minor allele frequencies were as expected (27.6%,
26.0%), and concordance across duplicates was 100%.
Logistic regression in SAS v. 8 (SAS Institute) was used to
estimate odds ratios (ORs) and 95% confidence intervals
(CIs), primarily assuming an ordinal effect with simple
tests for trend; heterozygous and minor allele
homozygous ORs were also estimated. Ovarian cancer
analyses were adjusted for age and region of residence;
breast cancer analyses were additionally adjusted for oral
contraceptive use, hormone therapy use, age at first birth,
age at menarche, menopausal status, and smoking pack
years. Stratified analyses were performed on sub-groups of
menopausal status, BMI, family history, and estrogen,
progesterone, and HER2 receptor status (breast cancer)
and age, family history, BMI, stage, grade, histology, and
tumor behavior (ovarian cancer).
Results
For both breast and ovarian cancer, no overall association
with risk was observed (per-allele OR, 95% CI; breast
1.04, 0.89-1.22; ovarian 0.96, 0.77-1.20). Breast cancer
stratified analyses revealed no associations (p's > 0.05)
among groups defined by menopausal status, BMI, family
history, or tumor histology (Table 1). Assuming inde-
pendent genotype effects (co-dominance), differential
risk of breast cancer by genotype for HER2 positive was
suggested (GT vs GG 1.68, 1.12-2.53; TT vs GG 0.49, 0.17-
1.45; 2 d.f. p = 0.01). Exploratory analyses assuming dom-
inance (GT/TT v GG) suggested elevated breast cancer
risks for pre-menopausal (1.46, 0.99-2.15; p = 0.06),
HER2 positive (1.48, 1.00-2.01; p = 0.05), and triple neg-
ative cases (2.01, 1.10-3.67; p = 0.02). Although sub-
Table 1: TCF7L2 rs12255372 and risk of breast cancer
N N Ordinal OR (95% CI) Co-Dominant ORs (95% CI)
Cases Controls Per T-allele P (trend) GT v GG TT v GG P (2 d.f.)
Total --- 779 830 1.04 (0.89-1.22) 0.62 1.16 (0.93-1.43) 0.92 (0.62-1.36) 0.31
Menopausal Pre 268 213 1.28 (0.94-1.75) 0.12 1.51 (1.01-2.26) 1.21 (0.56-2.61) 0.14
status Post 467 573 0.95 (0.77-1.16) 0.59 1.03 (0.78-1.34) 0.79 (0.49-1.29) 0.60
BMI ≤ 25.9 341 394 1.07 (0.84-1.37) 0.59 1.25 (0.90-1.73) 0.91 (0.50-1.64) 0.34
> 25.9 406 393 1.03 (0.82-1.30) 0.78 1.13 (0.83-1.54) 0.92 (0.52-1.63) 0.66
Family No 424 480 1.04 (0.84-1.30) 0.70 1.09 (0.81-1.46) 1.02 (0.60-1.73) 0.85
history Yes 336 312 0.99 (0.77-1.28) 0.95 1.25 (0.89-1.76) 0.68 (0.36-1.28) 0.14
Estrogen Positive 472 830 1.09 (0.91-1.31) 0.34 1.16 (0.90-1.49) 1.10 (0.70-1.71) 0.50
Receptor (ER) Negative 107 830 1.11 (0.81-1.52) 0.52 1.41 (0.92-2.17) 0.84 (0.36-1.96) 0.21
Progesterone Positive 429 830 1.21 (0.93-1.35) 0.23 1.19 (0.92-1.54) 1.15 (0.73-1.81) 0.39
Receptor (PR) Negative 147 830 1.00 (0.76-1.32) 0.99 1.19 (0.82-1.71) 0.74 (0.35-1.56) 0.40
HER2 status Positive 122 830 1.14 (0.83-1.55) 0.42 1.68 (1.12-2.53) 0.49 (0.17-1.45) 0.01
Negative 269 830 1.02 (0.82-1.27) 0.85 1.04 (0.78-1.40) 1.01 (0.60-1.70) 0.96
ER, PR, HER2 All Negative 51 842 1.47 (0.95-2.26) 0.08 2.16 (1.16-4.01) 1.36 (0.43-4.30) 0.05
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of 
residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), 
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groups were limited in size, these results are consistent
with involvement of rs12255372 in non-luminal tumors.
Analyses among ovarian cancer sub-groups did not sug-
gest varied associations by age, BMI, family history, stage,
grade, histology, or tumor behavior (Table 2). A signifi-
cant association (p = 0.02) among 12 cases with grade 1
disease compared to 458 controls is likely due to chance,
as the number of strata examined was large, sample size
was small, no trend with grade was seen, and no biologi-
cal explanation fits this observation.
Discussion
TCF7L2 has received much recent attention, as a consist-
ently-replicated association that originated out of a tradi-
tional genetic linkage scan [3] that also appears
consistently as a "top hit" for several phenotypes in
genome-wide association studies [13]. Although associa-
tion between rs12255372 and risk of Type 2 diabetes is
thought to be due to impairment of insulin secretion [14],
TCF7L2 has also long been known to have a role in Wnt/
β-catenin signaling. Deregulation of the Wnt pathway is
involved in the mechanisms of carcinogenesis [15], and
mutations in Wnt-related genes have been detected in
many cancers [16-18], indicating somatic mutations are
important deregulation mechanisms of Wnt signaling. In
breast cancer, we recently demonstrated that SNPs in the
AXIN2 and APC genes are associated with risk [11]. In
ovarian cancer, somatic mutations in CTNNB1 (encoding
β-catenin) are directly linked to carcinogenic transforma-
tion, but they are rare and mostly found in endometrioid
adenocarcinomas [19]. Ovarian expression studies show
differences for distinct cellular components of the Wnt
pathway between normal and cancer cells [20] implicat-
ing Wnt signaling in the molecular events leading to ovar-
ian cancer despite the fact that gene mutations are
uncommon [21].
Because of the importance of Wnt/β-catenin signaling in
breast and ovarian cancer, TCF7L2's critical role in com-
bining with β-catenin, clear associations of rs12255372
with non-cancer phenotypes, and suggestive evidence of
association with cancer phenotypes, we hypothesized that
genotypes at this SNP may be associated with risk of
breast and/or ovarian cancer. However, no strong associa-
tion was suggested in our analysis of almost 800 breast
cancer cases and 850 controls, and almost 400 ovarian
cancer cases and 450 controls.
These results contrast with a smaller analysis of 592 famil-
ial breast cancer cases and 735 controls which showed a
per-allele OR of 1.19 (95% CI 1.01-1.42) [6]. Our breast
cancer case-control series provided 80% power to detect
an OR as low as 1.22, assuming a minor allele frequency
of 0.25 and a Type I error rate of 0.05 and was adequately
Table 2: TCF7L2 rs12255372 and risk of ovarian cancer
N N Ordinal OR (95% CI) Co-Dominant ORs (95% CI)
Cases Controls Per T-allele P (trend) GT v GG TT v GG P (2 d.f.)
Total --- 391 458 0.96 (0.77-1.20) 0.75 0.95 (0.71-1.26) 0.97 (0.56-1.68) 0.93
Age < 60 191 206 1.15 (0.83-1.59) 0.40 1.04 (0.68-1.58) 1.60 (0.70-3.69) 0.54
60+ 200 252 0.82 (0.60-1.10) 0.19 0.87 (0.58-1.28) 0.60 (0.28-1.28) 0.38
BMI ≤ 26.2 164 226 1.00 (0.72-1.39) 1.00 0.96 (0.62-1.47) 1.08 (0.47-2.44) 0.96
> 26.2 211 203 0.94 (0.69-1.30) 0.74 0.98 (0.65-1.49) 0.84 (0.38-1.84) 0.91
Family No 329 403 0.93 (0.74-1.18) 0.58 1.01 (0.74-1.37) 0.77 (0.43-1.38) 0.66
history Yes 50 32 2.18 (0.89-5.34) 0.09 1.20 (0.40-3.61) 21.1 (1.34-334) 0.09
Stage 1 103 458 1.00 (0.70-1.41) 0.99 0.95 (0.60-1.50) 1.08 (0.44-2.63) 0.96
2 29 458 1.24 (0.65-2.35) 0.51 1.09 (0.49-2.41) 2.25 (0.28-17.8) 0.74
3 196 458 0.86 (0.66-1.13) 0.28 0.82 (0.58-1.18) 0.80 (0.41-1.56) 0.52
4 55 458 1.26 (0.78-2.02) 0.35 1.54 (0.82-2.89) 1.07 (0.35-3.26) 0.40
Grade 0 64 458 1.26 (0.80-1.99) 0.32 1.12 (0.64-1.95) 2.34 (0.52-10.4) 0.52
11 2 4 5 8 0.37 (0.16-0.88) 0.02 0.19 (0.04-0.94) 0.15 (0.02-1.11) 0.09
2 41 458 0.88 (0.53-1.46) 0.62 1.09 (0.54-2.23) 0.61 (0.21-1.81) 0.60
3 146 458 0.99 (0.73-1.35) 0.94 0.97 (0.65-1.44) 1.02 (0.46-2.27) 0.98
4 121 458 0.93 (0.68-1.29) 0.68 0.93 (0.60-1.42) 0.89 (0.40-1.98) 0.92
Histology Serous 232 458 0.93 (0.72-1.21) 0.60 0.87 (0.62-1.21) 1.00 (0.52-1.93) 0.70
Mucinous 27 458 1.24 (0.63-2.44) 0.53 0.89 (0.40-1.97) n.a. 0.96
Endometriod 64 458 0.94 (0.62-1.41) 0.76 1.55 (0.84-2.86) 0.53 (0.23-1.22) 0.07
Clear cell 25 458 1.04 (0.54-2.00) 0.91 0.81 (0.35-1.90) 1.91 (0.23-15.7) 0.70
Mixed cell 32 458 1.42 (0.76-2.68) 0.27 1.30 (0.60-2.80) 2.73 (0.35-21.4) 0.55
Behavior Malignant 327 458 0.93 (0.74-1.17) 0.52 0.92 (0.68-1.25) 0.87 (0.49-1.53) 0.81
Borderline 64 458 1.20 (0.76-1.88) 0.43 1.03 (0.59-1.80) 2.29 (0.52-10.2) 0.55
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age (unless 
used as stratifiying variable) and region of residence; n.a., not estimatable, bold indicates p < 0.05.BMC Cancer 2009, 9:312 http://www.biomedcentral.com/1471-2407/9/312
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powered to detect similar modest associations. Addition-
ally, there may be an association in smaller subsets con-
sistent with non-luminal tumors. No ovarian cancer
analyses have been reported to date. Previous reports in
other traits suggested varied association by BMI, family
history, and tumor features; although subset sample sizes
were small, we found no evidence for association between
rs12255372 and risk in any subset.
Conclusion
Despite strong prior evidence that this SNP may play a
role women's cancer susceptibility, we conclude that vari-
ation in TCF7L2 is not likely to be associated with risk of
non-familial breast cancer or ovarian cancer. Because very
modest associations could not be definitively ruled out
and because increased risk may exist for triple-negative
breast cancer cases, much larger studies will be required
for more precise estimation of rs12255372's role in cancer
susceptibility. In addition, given the role of Wnt/β-catenin
signaling in cancer, identified associations of SNPs in the
AXIN2  and  APC  genes with breast cancer and the
increased risk conferred by family history for these condi-
tions even after accounting for known syndromes, addi-
tional SNPs and genes within this pathway warrant
further study.
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